Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety
A retrospective study of off-label, at-home use
Datos Bibliográficos
| ID | 15528186 |
|---|---|
| Autores | Kazi Hassan (autor de correspondencia), William M Struthers (Wheaton College - Illinois), Aditya Sankarabhotla, Patrick J Davis, Patrick Davis |
| Año | 2022 |
| Volumen | 13 |
| Páginas | 992624-992624 |
| Fecha de publicación | 2022-09-28 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Frontiers in Psychiatry (JOURNAL) |
| Identificadores de la revista | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Editorial | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2022.992624 |
| PMID | 36245861 |
| OpenAlex | W4297329384 |
| Idioma | EN |
| Citas recibidas | 3 |
| Referencias citadas | 44 |
Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve ketamine tablets (RDT) at-home for depression and anxiety. Intake scores on the Generalized Anxiety Disorder Screener (GAD-7) and Patient Health Questionnaire (PHQ-9) were compared to scores after treatments of three doses of ketamine RDT, and after six doses of ketamine RDT. After three doses of SL ketamine, 47.6% of patients showed a significant decrease in PHQ-9 scores, and 47.6% of patients showed a significant reduction in GAD-7 scores. Reduction rates were higher in those patients who completed a clinically recommended six doses of RDT ketamine. This study demonstrates that SL ketamine is a novel, safe, and effective treatment for TRD and treatment-resistant anxiety. SL ketamine offers an alternative therapeutic approach to IV ketamine when treating those with TRD
Adverse effect · Anesthesia · Antidepressant · Anxiety · Depression (economics · Ketamine · Psychiatry · Tolerability · Treatment-resistant depression · Alcoholism and Thiamine Deficiency · Medicine · Treatment of Major Depression · Tryptophan and brain disorders · Pharmacology
| Obras citantes distintas | 3 |
|---|---|
| Citas por año | 1 |
| Intervalo de citas | 2023 - 2024 (2) |
| Velocidad de citación | recent |
| Altamente citado | No |
| Tipos de cita | Neutras: 3 |